Paul Moreton

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Paul Moreton, Ben Kennedy, Guy Lucas et al. · Journal of Clinical Oncology · 2005 · 421 citations

Medicine, Hematology, Oncology +16

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

G Hale, Peppy Rebello, Lee Brettman et al. · Blood · 2004 · 182 citations · Full text

Pharmacy, Immunology, Oncology +14

Minimal residual disease is an independent predictor for 10-year survival in CLL

Marwan Kwok, Andy C. Rawstron, Abraham Varghese et al. · Blood · 2016 · 135 citations · Full text

Medicine, Pathology, Survival Analysis +12

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Peter Hillmen, John G. Gribben, George Follows et al. · Journal of Clinical Oncology · 2014 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

Andy C. Rawstron, Ben Kennedy, Paul Moreton et al. · Blood · 2003 · 66 citations · Full text

Medicine, Immunology, Oncology +13